DescriptionAntidepressant efficacy of dextromethorphan and bupropion (Auvelity) versus placebo in the GEMINI trial.png
English: Antidepressant efficacy as measured by change in mean total scores on the Montgomery-Asberg Depression Rating Scale (MADRS) over 6 weeks with dextromethorphan/bupropion (Auvelity) (n=156) versus placebo (n=162) in people with major depressive disorder in the GEMINI phase 3 randomized controlled trial. The formulation and dosage were oral extended-release dextromethorphan hydrobromide 45 mg and bupropion 105 mg twice daily (total doses of 90 mg/day and 210 mg/day, respectively).
Sources of the values:
(May 2022). "Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI)". J Clin Psychiatry83 (4). DOI:10.4088/JCP.21m14345. PMID35649167.
to share – to copy, distribute and transmit the work
to remix – to adapt the work
Under the following conditions:
attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the same or compatible license as the original.